| Vanilloid (Capsaicin) receptors and mechanisms A Szallasi, PM Blumberg Pharmacological reviews 51 (2), 159-212, 1999 | 2389 | 1999 |
| The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept A Szallasi, DN Cortright, CA Blum, SR Eid Nature reviews Drug discovery 6 (5), 357-372, 2007 | 1056 | 2007 |
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human É Mezey, ZE Toth, DN Cortright, MK Arzubi, JE Krause, R Elde, A Guo, ... Proceedings of the National Academy of Sciences 97 (7), 3655-3660, 2000 | 973 | 2000 |
| Transient receptor potential channels as therapeutic targets MM Moran, MA McAlexander, T Bíró, A Szallasi Nature reviews Drug discovery 10 (8), 601-620, 2011 | 645 | 2011 |
| Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine B Nilius, A Szallasi Pharmacological reviews 66 (3), 676-814, 2014 | 531 | 2014 |
| Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper A Szallasi, PM Blumberg Neuroscience 30 (2), 515-520, 1989 | 507 | 1989 |
| Biochemical pharmacology of the vanilloid receptor TRPV1: an update DN Cortright, A Szallasi European journal of biochemistry 271 (10), 1814-1819, 2004 | 439 | 2004 |
| Transient receptor potential (TRP) channels: a clinical perspective Y Kaneko, A Szallasi British journal of pharmacology 171 (10), 2474-2507, 2014 | 405 | 2014 |
| Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? H Knotkova, M Pappagallo, A Szallasi The Clinical journal of pain 24 (2), 142-154, 2008 | 364 | 2008 |
| Targeting TRP channels for pain relief JD Brederson, PR Kym, A Szallasi European journal of pharmacology 716 (1-3), 61-76, 2013 | 351 | 2013 |
| Endovanilloid signaling in pain V Di Marzo, PM Blumberg, A Szallasi Current opinion in neurobiology 12 (4), 372-379, 2002 | 328 | 2002 |
| Vanilloid receptors: new insights enhance potential as a therapeutic target A Szallasi, PM Blumberg Pain 68 (2-3), 195-208, 1996 | 316 | 1996 |
| Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root anglion membranes A Szallasi, PM Blumberg Brain research 524 (1), 106-111, 1990 | 313 | 1990 |
| Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine G Appendino, A Szallasi Life sciences 60 (10), 681-696, 1997 | 259 | 1997 |
| Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms A Szallasi, MJ Gunthorpe Current pharmaceutical design 14 (1), 32-41, 2008 | 254 | 2008 |
| New perspectives on enigmatic vanilloid receptors A Szallasi, V Di Marzo Trends in neurosciences 23 (10), 491-497, 2000 | 253 | 2000 |
| The vanilloid (capsaicin) receptor: receptor types and species differences A Szallasi General Pharmacology: The Vascular System 25 (2), 223-243, 1994 | 252 | 1994 |
| Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic … A Szallasi, S Nilsson, T Farkas-Szallasi, PM Blumberg, T Hökfelt, ... Brain research 703 (1-2), 175-183, 1995 | 251 | 1995 |
| Advances in TRP channel drug discovery: from target validation to clinical studies AP Koivisto, MG Belvisi, R Gaudet, A Szallasi Nature reviews Drug discovery 21 (1), 41-59, 2022 | 246 | 2022 |
| Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor A Szallasi, PM Blumberg Life sciences 47 (16), 1399-1408, 1990 | 228 | 1990 |
